Management of Important Adverse Events Associated with Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Inotuzumab ozogamicin (InO) is an anti-CD22 antibody-calicheamicin conjugate being investigated in patients with acute lymphoblastic leukemia (ALL). The phase 3 INO-VATE study demonstrated superior efficacy of InO compared with standard therapy among adult patients with relapsed or refractory ALL (NCT01564784; doi: 10.1056/NEJMoa1509277). Overall tolerability of InO was confirmed, but several clinically important adverse events (AEs) associated with InO were identified, including neutropenia, thrombocytopenia, infusion-related reactions, tumor lysis syndrome, prolonged QT syndrome, and veno-occlusive disease (VOD).

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Partow Kebriaei, Koen van Besien, Corey Cutler, Marcos de Lima, Sergio Giralt, Stephanie Lee, David Marks, Akil Merchant, Wendy Stock, Matthias Stelljes Source Type: research